$7.47
4.96%
Nasdaq, Nov 16, 04:25 pm EST. Closed.
ISIN
US81642T1007
Symbol
SLS

SELLAS Life Sciences Group, Inc. Stock price

$7.47
-2.51 25.15% 1M
+0.18 2.47% 6M
+3.70 98.14% YTD
+6.06 429.79% 1Y
+6.55 711.34% 3Y
+0.22 3.03% 5Y
-5,272.53 99.86% 10Y
-1.24 14.24% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-0.39 4.96%
ISIN
US81642T1007
Symbol
SLS
Industry

Is SELLAS Life Sciences Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.4b
Net debt
positive
Cash
$138.3m
Shares outstanding
201.9m
Valuation
P/E
negative
P/S | estimate
- | 69.5
EV/Sales | estimate
- | 63.2
EV/FCF | ex SBC
negative | negative
P/B
11.1
Financial Health
Equity Ratio
90.5%
Return on Equity
-
ROCE
-25.6%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.8m | -
SBC as % of FCF
-
SBC Growth 1Y
56.8%
Share Count Growth 1Y
101.2%
Shareholder Yield
-
Financials
Revenue | estimate
$0.0 | $21.9m
EBITDA
-
EBIT
$-35.2m
Net Income
$-32.5m
Free Cash Flow | ex SBC
$-28.4m | $-31.2m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-29.6%
Net Income
-23.6%
Free Cash Flow
10.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
28.2%
Employees
13
Rev per Employee
-

SELLAS Life Sciences Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

Buy
83%
Hold
17%

SELLAS Life Sciences Group, Inc. Events

Past Events
NOV
10
Q3 2026 Earnings Call
7 days ago
OCT
29
Special Call - SELLAS Life Sciences Group, Inc.
about one year ago

Financial data from SELLAS Life Sciences Group, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
31% 31%
-
- Research and Development Expense 20 20
28% 28%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -35 -35
30% 30%
-
Net Profit -32 -32
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about SELLAS Life Sciences Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SELLAS Life Sciences Group, Inc. Stock News

Neutral
GlobeNewsWire
●
about one hour ago
- REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -
Neutral
GlobeNewsWire
●
5 days ago
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 - - $134.7 Million in Cash and Cash Equivalents as of September 30, 2026 - NEW YORK, Nov. 12, 2026 (GLOBE N...
Neutral
GlobeNewsWire
●
20 days ago
- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
More SELLAS Life Sciences Group, Inc. News

Company Profile

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Head office United States
CEO Dr. Stergiou
Employees 13
Founded 2006
Website www.sellaslifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today